| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
29,228 |
23,126 |
$1.93M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
23,671 |
18,454 |
$1.11M |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
3,779 |
3,082 |
$305K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
4,047 |
3,216 |
$293K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
3,004 |
2,298 |
$223K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
1,467 |
1,161 |
$209K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
1,955 |
1,452 |
$131K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
5,803 |
4,703 |
$92K |
| 87428 |
|
1,099 |
835 |
$70K |
| 90686 |
|
5,780 |
4,651 |
$69K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
789 |
655 |
$63K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
2,560 |
2,052 |
$60K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
3,333 |
2,881 |
$52K |
| 94664 |
|
3,580 |
2,871 |
$46K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
1,279 |
1,019 |
$45K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,065 |
878 |
$43K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
460 |
361 |
$35K |
| 99000 |
|
1,546 |
1,373 |
$35K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,317 |
1,128 |
$32K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
533 |
460 |
$27K |
| 90670 |
|
1,377 |
1,100 |
$27K |
| 90734 |
|
1,394 |
981 |
$24K |
| 90620 |
|
1,310 |
996 |
$24K |
| 90649 |
|
1,814 |
1,451 |
$23K |
| 90651 |
|
283 |
262 |
$20K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
687 |
571 |
$17K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,481 |
1,076 |
$12K |
| 90716 |
|
592 |
459 |
$10K |
| 99406 |
|
1,883 |
1,409 |
$10K |
| 94375 |
|
299 |
249 |
$9K |
| 90656 |
|
511 |
407 |
$9K |
| 90698 |
|
726 |
553 |
$9K |
| 0071A |
|
206 |
199 |
$9K |
| 90707 |
|
566 |
431 |
$8K |
| 0072A |
|
186 |
174 |
$8K |
| 90715 |
|
583 |
426 |
$7K |
| 90633 |
|
537 |
404 |
$6K |
| 90619 |
|
307 |
268 |
$5K |
| 90677 |
|
105 |
79 |
$5K |
| 90744 |
|
311 |
249 |
$3K |
| 99215 |
Prolong outpt/office vis |
122 |
84 |
$3K |
| 99336 |
|
123 |
74 |
$2K |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
1,452 |
1,067 |
$2K |
| 95930 |
|
37 |
34 |
$2K |
| 99384 |
|
18 |
13 |
$1K |
| G0008 |
Administration of influenza virus vaccine |
194 |
122 |
$1K |
| 90688 |
|
59 |
28 |
$1K |
| 90696 |
|
46 |
26 |
$975.58 |
| 90648 |
|
117 |
88 |
$975.44 |
| 90685 |
|
110 |
93 |
$959.56 |
| 90700 |
|
107 |
77 |
$670.84 |
| 90723 |
|
33 |
28 |
$666.50 |
| 93000 |
|
14 |
12 |
$188.21 |
| 91307 |
|
184 |
163 |
$187.50 |
| 99490 |
Ccm add 20min |
38 |
38 |
$161.10 |
| 90681 |
|
16 |
14 |
$102.40 |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
3,247 |
2,624 |
$13.75 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
208 |
172 |
$6.41 |
| G0439 |
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit |
13 |
12 |
$0.00 |
| 90461 |
|
1,270 |
973 |
$0.00 |
| 82947 |
|
13 |
13 |
$0.00 |
| 99072 |
|
14 |
14 |
$0.00 |
| Q2038 |
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) |
15 |
14 |
$0.00 |